Skip to Main Content

Merck said Tuesday that it has begun the process of submitting the evidence it will use to seek approval for its experimental Ebola vaccine, a crucial step in the drug maker’s long effort to bring the vaccine to market.

The company said it hopes to complete the filing process sometime next year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED